Maziar Shabestari1, Yashar R Shabestari1, Maria A Landin1, Milaim Pepaj2, Timothy P Cleland3, Janne E Reseland1, Erik F Eriksen4,5. 1. Department of Biomaterials, University of Oslo, Oslo, Norway. 2. Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway. 3. Department of Chemistry, University of Texas, Austin, TX, USA. 4. Department of Endocrinology, Oslo University Hospital (Aker), Oslo, Norway. 5. Faculty of Medicine, Institue of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
AIM: To assess tissue level changes of proteome and cytokine profiles of subchondral bone in hip osteoarthritis (OA) affected by bone marrow lesions (BMLs). We compared significant protein level differences in osteoarthritic bone with BMLs to control bone without bone marrow lesions. METHODS: Subchondral bone biopsies were taken from femoral heads of end-stage osteoarthritis patients with (BML, n = 21) and without (CON, n = 9) BMLs. Proteins were extracted through a standardized Trizol protocol and used in the subsequent analyses. Angiogenesis and bone markers were assessed using multiplex immunoassays (Luminex). Liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed to detect significant differences in proteome and peptide profiles between BML and CON. RESULTS: Multiplex immunoassays revealed increased tissue contents of vascular endothelial growth factors (VEGF-A/C/D), endothelin-1, angiopoietin-2 and interleukin-6 (IL-6) in bone with BMLs compared to control bone, whereas osteoprotegerin levels were reduced. Mass spectrometry demonstrated pronounced increase in the levels of hemoglobin (73-fold), serum albumin (30-fold), alpha-1-antitrypsin (9-fold), apolipoprotein A1 (4.7-fold), pre-laminin-A/C (3.7-fold) and collagen-alpha1-XII (3-fold) in BMLs, while aggrecan core protein (ACAN) and hyaluronan and proteoglycan link protein 1 (HAPL1) decreased 37- and 29-fold respectively. CONCLUSION: Reduced osteoprotegerin, ACAN and HAPL1 are consistent with osteoclastic activation and high remodeling activity in BMLs. The pronounced increase in angiogenesis markers, hemoglobin and serum albumin support the presence of increased vascularity in subchondral bone affected by BMLs in OA. VEGFs and IL-6 are known nociceptive modulators, and increased levels are in keeping with pain being a clinical feature frequently associated with BMLs.
AIM: To assess tissue level changes of proteome and cytokine profiles of subchondral bone in hip osteoarthritis (OA) affected by bone marrow lesions (BMLs). We compared significant protein level differences in osteoarthritic bone with BMLs to control bone without bone marrow lesions. METHODS: Subchondral bone biopsies were taken from femoral heads of end-stage osteoarthritispatients with (BML, n = 21) and without (CON, n = 9) BMLs. Proteins were extracted through a standardized Trizol protocol and used in the subsequent analyses. Angiogenesis and bone markers were assessed using multiplex immunoassays (Luminex). Liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed to detect significant differences in proteome and peptide profiles between BML and CON. RESULTS: Multiplex immunoassays revealed increased tissue contents of vascular endothelial growth factors (VEGF-A/C/D), endothelin-1, angiopoietin-2 and interleukin-6 (IL-6) in bone with BMLs compared to control bone, whereas osteoprotegerin levels were reduced. Mass spectrometry demonstrated pronounced increase in the levels of hemoglobin (73-fold), serum albumin (30-fold), alpha-1-antitrypsin (9-fold), apolipoprotein A1 (4.7-fold), pre-laminin-A/C (3.7-fold) and collagen-alpha1-XII (3-fold) in BMLs, while aggrecan core protein (ACAN) and hyaluronan and proteoglycan link protein 1 (HAPL1) decreased 37- and 29-fold respectively. CONCLUSION: Reduced osteoprotegerin, ACAN and HAPL1 are consistent with osteoclastic activation and high remodeling activity in BMLs. The pronounced increase in angiogenesis markers, hemoglobin and serum albumin support the presence of increased vascularity in subchondral bone affected by BMLs in OA. VEGFs and IL-6 are known nociceptive modulators, and increased levels are in keeping with pain being a clinical feature frequently associated with BMLs.
Authors: Emmanouil Fandridis; George Apergis; Dimitrios S Korres; Konstantinos Nikolopoulos; Aristides B Zoubos; Issidora Papassideri; Ioannis P Trougakos Journal: In Vivo Date: 2011 Sep-Oct Impact factor: 2.155
Authors: Maja R Radojčić; Christian S Thudium; Kim Henriksen; Keith Tan; Rolf Karlsten; Amanda Dudley; Iain Chessell; Morten A Karsdal; Anne-Christine Bay-Jensen; Michel D Crema; Ali Guermazi Journal: Pain Date: 2017-07 Impact factor: 6.961
Authors: M van der Esch; J Knoop; M van der Leeden; L D Roorda; W F Lems; D L Knol; J Dekker Journal: Osteoarthritis Cartilage Date: 2015-01-14 Impact factor: 6.576
Authors: Sunita Suri; Sarah E Gill; Sally Massena de Camin; Deborah Wilson; Daniel F McWilliams; David A Walsh Journal: Ann Rheum Dis Date: 2007-04-19 Impact factor: 19.103
Authors: Devon Hominick; Asitha Silva; Noor Khurana; Ying Liu; Paul C Dechow; Jian Q Feng; Bronislaw Pytowski; Joseph M Rutkowski; Kari Alitalo; Michael T Dellinger Journal: Elife Date: 2018-04-05 Impact factor: 8.140
Authors: Andrea Franceschini; Damian Szklarczyk; Sune Frankild; Michael Kuhn; Milan Simonovic; Alexander Roth; Jianyi Lin; Pablo Minguez; Peer Bork; Christian von Mering; Lars J Jensen Journal: Nucleic Acids Res Date: 2012-11-29 Impact factor: 16.971
Authors: Nina Schmidt; Inga Irle; Kamilla Ripkens; Vanda Lux; Jasmin Nelles; Christian Johannes; Lee Parry; Kirsty Greenow; Sarah Amir; Mara Campioni; Alfonso Baldi; Chio Oka; Masashi Kawaichi; Alan R Clarke; Michael Ehrmann Journal: BMC Cancer Date: 2016-07-07 Impact factor: 4.430
Authors: Alvaro Del Real; Sergio Ciordia; Carolina Sañudo; Carmen Garcia-Ibarbia; Adriel Roa-Bautista; Javier G Ocejo-Viñals; Fernando Corrales; Jose A Riancho Journal: Metabolites Date: 2022-04-28
Authors: Clara Sanjurjo-Rodríguez; Rachel E Crossland; Monica Reis; Hemant Pandit; Xiao-Nong Wang; Elena Jones Journal: Stem Cells Int Date: 2021-10-09 Impact factor: 5.443
Authors: Guus G H van den Akker; Marjolein M J Caron; Mandy J Peffers; Tim J M Welting Journal: Curr Opin Rheumatol Date: 2022-01-01 Impact factor: 5.006